A recent comprehensive review of the literature of the PubMed database and of the clinical experiences of oncologists and dermatologists concerning patients with regorafenib (Stivarga) related hand-foot skin reaction (HFSR) was published in the [...]
A Phase II clinical trial comparing Imatinib alternated with Regorafenib to Imatinib alone is currently underway and recruiting in Australia. The trial, sponsored by the Australasian Gastro-Intestinal Trials Group, looks to examine the feasibility of [...]
The National Health Service (NHS) in the United Kingdom has announced plans to halt funding through the Cancer Drug Fund for regorafenib (Stivarga), thereby preventing GIST patients from having access to this life-saving medication.We at [...]
The European Commission recently announced that Stivarga (regorafenib) from Bayer has been approved in the European Union (EU) as a third line treatment for GIST.
Health Canada has expanded approval for the use of Stivarga to fight Gastrointestinal Stromal Tumours (GIST), according to an article from CNW. Bayer announced that Stivarga will now be available for treatment of adult patients with [...]
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.
Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.
Trial investigators for the Global Phase 3 GRID trial reported that the Bayer Pharmaceuticals’ drug regorafenib (BAY 73-4506) has the potential to fill the unmet need for advanced GIST patients progressing after imatinib and sunitinib. [...]